• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRI™ Website
      • ISPRI Downselect™
      • ISPRI Quantify™
      • ISPRI Analyze™
      • ISPRI Evaluate™
      • ISPRI-HCP™
      • ISPRI Design™
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAX™
      • EpiCC™
      • Ancer®
      • PreVAX™
    • Lab Services
      • All In Vitro Assays
      • Generic Peptide PANDA® Assays
    • Consulting Services
      • Trusted Expert Advice (TEA)
      • IRA / ISI Regulatory Writing Support
    • Why Immunogenicity Risk Assessment?
    • Why EpiVax?
  • About Us
    • Company History
    • Leadership
    • Careers
  • Press
    • News
    • Events
    • Publications
    • Blog
  • Contact Us
EpiVax Collaborates with Leidos on Malaria Vaccine Research, Series of Papers Published in Frontiers In Immunology

EpiVax Collaborates with Leidos on Malaria Vaccine Research, Series of Papers Published in Frontiers In Immunology

by Elena Iemma | Nov 17, 2021 | News

PROVIDENCE, RI, November 2021 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) announces the publication of three papers focusing on malaria vaccine efficacy, part of a collaboration with Leidos, the University of Georgia Center for Vaccines and Immunology, the University...
EpiVax Collaborates with Leidos on Malaria Vaccine Research, Series of Papers Published in Frontiers In Immunology

EpiVax Licenses Tregitope Technology to Maruho Co., Ltd. for development of Tregitope-based Therapies to Treat Autoimmune Condition

by Elena Iemma | Nov 4, 2021 | News

PROVIDENCE, RI, November 4, 2021 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) is pleased to announce an important commercial licensing agreement with Maruho Co., Ltd. (“Maruho”) for EpiVax’s patented Tregitope technology. This marks an exciting step for Maruho and...
EpiVax Collaborates with Leidos on Malaria Vaccine Research, Series of Papers Published in Frontiers In Immunology

Immunogenicity Expert and FDA Alum Dr. Amy Rosenberg Joins EpiVax

by Elena Iemma | Jul 6, 2021 | News

PROVIDENCE, RI, July 6, 2021 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) is pleased to announce that Dr. Amy Rosenberg is leaving the FDA’s Division of Therapeutic Proteins, CDER, which she led for over 20 years, to join EpiVax as Senior Director of Immunology and...
EpiVax Collaborates with Leidos on Malaria Vaccine Research, Series of Papers Published in Frontiers In Immunology

EpiVax Identifies T cell Epitopes critical to robust T cell immune response in SARS-CoV-2 , Results Published in NPJ Vaccines

by Elena Iemma | May 17, 2021 | News

PROVIDENCE, RI, May 17, 2021 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) announces the publication “Highly conserved, non-human-like, and cross-reactive SARS-CoV-2 T cell epitopes for COVID-19 vaccine design and validation” in NPJ Vaccines. This research identifies...
Improving Cancer Survival Prediction:  A New Approach with EpiVax Therapeutics’ Ancer Platform

Improving Cancer Survival Prediction: A New Approach with EpiVax Therapeutics’ Ancer Platform

by Elena Iemma | May 13, 2021 | News

PROVIDENCE, RI, May 13, 2021 /PRNewswire/ — EpiVax Therapeutics, Inc. (“EVT”) announces the publication “Multi‑step screening of neoantigens’ HLA and TCR‑interfaces improves prediction of survival” in Scientific Reports. This study demonstrates a superior method...
EpiVax Collaborates with Leidos on Malaria Vaccine Research, Series of Papers Published in Frontiers In Immunology

EpiVax Demonstrates Antigen-Specific Tolerance Induction in Allergy with Tregitopes, Results Published in Frontiers in Immunology

by Elena Iemma | Apr 27, 2021 | News

PROVIDENCE, RI, April 27, 2021 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) announces the publication “Tregitopes Improve Asthma by Promoting Highly Suppressive and Antigen-Specific Tregs” in Frontiers in Immunology. This research highlights Tregitopes as a promising...
« Older Entries
Next Entries »

Recent Posts

  • EpiVax Announces Laboratory Expansion and Streamlined, NAM-Centric In Vitro Services    
  • Replacing Animal Models with Human-Relevant New Approach Methodologies (NAMs) for Immunogenicity in Clinic
  • EpiVax Enters its Next Chapter with SV Health Investors
  • Immunogenicity Risk Assessment Outputs to Drive a Streamlined, Risk-Based Preclinical and Clinical Strategy
  • Immunogenicity Risk Assessment Outputs to Drive a Streamlined, Risk-Based Preclinical and Clinical Strategy

Recent Comments

No comments to show.

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

LinkedIn

About Us

Careers

News

Events

Publications

Contact Us

Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}